Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Dr. Lal PathLabs Limited
  6. Summary
    539524   INE600L01024

DR. LAL PATHLABS LIMITED

(539524)
  Report
End-of-day quote Bombay Stock Exchange  -  2022-09-22
2515.55 INR   +2.95%
08/29Crisil Assigns AA- Rating on Dr. Lal PathLabs' Bank Loans; Outlook Positive
MT
08/01UBS Adjusts Dr. Lal Pathlabs' Price Target to 2,700 Indian Rupees From 2,800 Rupees, Keeps at Buy
MT
07/29Dr. Lal PathLabs' Consolidated Net Profit Slides in Fiscal Q1; Shares Jump 6%
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   End-of-day quote. End-of-day quote Bombay Stock Exchange
09/19/2022 09/20/2022 09/21/2022 09/22/2022 09/23/2022 Date
2281.45 2335.45 2388.8 2443.4 2515.55 Last
57159 9394 14288 21199 12775 Volume
-0.75% +2.37% +2.28% +2.29% +2.95% Change
Estimated financial data (e)
Sales 2023 21 575 M 266 M 266 M
Net income 2023 2 981 M 36,7 M 36,7 M
Net cash position 2023 5 070 M 62,5 M 62,5 M
P/E ratio 2023 70,2x
Yield 2023 0,52%
Sales 2024 24 576 M 303 M 303 M
Net income 2024 3 707 M 45,7 M 45,7 M
Net cash position 2024 7 998 M 98,6 M 98,6 M
P/E ratio 2024 56,5x
Yield 2024 0,60%
Capitalization 210 B 2 584 M 2 584 M
EV / Sales 2023 9,48x
EV / Sales 2024 8,21x
Nbr of Employees 4 110
Free-Float 38,8%
More Financials
Company
Dr. Lal PathLabs Limited is engaged in providing diagnostic and related healthcare tests and services. The Company is also engaged in running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, and other pathological and radiological investigations. The Company offers a range of tests by condition,... 
More about the company
Ratings of Dr. Lal PathLabs Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about DR. LAL PATHLABS LIMITED
08/29Crisil Assigns AA- Rating on Dr. Lal PathLabs' Bank Loans; Outlook Positive
MT
08/01UBS Adjusts Dr. Lal Pathlabs' Price Target to 2,700 Indian Rupees From 2,800 Rupees, Ke..
MT
07/29Dr. Lal PathLabs' Consolidated Net Profit Slides in Fiscal Q1; Shares Jump 6%
MT
07/28TRANSCRIPT : Dr. Lal PathLabs Limited, Q1 2023 Earnings Call, Jul 28, 2022
CI
07/28DR LAL PATHLABS : Record Date
PU
07/28DR LAL PATHLABS : Dividend
PU
07/28Dr. Lal Pathlabs Limited Declares an Interim Dividend for the Financial Year 2022-23, P..
CI
07/28Dr. Lal PathLabs Limited Reports Earnings Results for the First Quarter Ended June 30, ..
CI
07/26UBS Adjusts Dr. Lal Pathlabs' Price Target to 2,800 Indian Rupees From 3,700 Rupees, Ke..
MT
06/30Dr. Lal Pathlabs Limited Declares Final Dividend for the Financial Year Ended March 31,..
CI
06/09DR LAL PATHLABS : Business Responsibility & Sustainability Report (BRSR)
PU
06/09Dr. Lal Pathlabs Limited Proposes Final Dividend for the Financial Year Ended March 31,..
CI
05/20Nomura Adjusts Dr. Lal Pathlabs' Price Target to 1,771 Indian Rupees From 2,465 Rupees,..
MT
05/17TRANSCRIPT : Dr. Lal PathLabs Limited, Q4 2022 Earnings Call, May 17, 2022
CI
05/17Dr. Lal Pathlabs Limited Proposes Final Dividend for the Year Ended March 31, 2022
CI
More news
News in other languages on DR. LAL PATHLABS LIMITED
08/29Crisil attribue la note AA- aux prêts bancaires de Dr. Lal PathLabs ; perspectives posi..
07/29Le bénéfice net consolidé de Dr. Lal PathLabs chute au premier trimestre de l'exercice ..
07/28Dr. Lal Pathlabs Limited déclare un dividende intérimaire pour l'exercice 2022-23, paya..
07/28Dr. Lal PathLabs Limited annonce ses résultats pour le premier trimestre se terminant l..
06/30Dr. Lal Pathlabs Limited déclare un dividende final pour l'exercice clos le 31 mars 202..
More news
Analyst Recommendations on DR. LAL PATHLABS LIMITED
More recommendations
ETFs positioned on DR. LAL PATHLABS LIMITEDETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Franklin FTSE India ETF Dist - USD0.1%-3.45%India
WisdomTree India Earnings Fund - USD0.02%-4.96%India
Franklin FTSE Asia ex Japan ETF - USD0.02%-4.91%Asia
IShares Core MSCI All Country World ex Cana...0%-2.64%World
IShares Core MSCI All Country World ex Cana...0%0.00%-World
More ETFs positioned on DR. LAL PATHLABS LIMITED
Chart DR. LAL PATHLABS LIMITED
Duration : Period :
Dr. Lal PathLabs Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DR. LAL PATHLABS LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Last Close Price 2 515,55 INR
Average target price 2 218,37 INR
Spread / Average Target -11,8%
EPS Revisions
Managers and Directors
Bharath Uppiliappan Chief Executive Officer
Ved Prakash Goel Chief Financial Officer
Arvind Lal Executive Chairman
Munender Soperna Chief Information Officer
Shankha Banerjee Chief Operating Officer
Sector and Competitors